company background image
AFT

AFT PharmaceuticalsNZSE:AFT Stock Report

Market Cap

NZ$429.2m

7D

1.5%

1Y

-16.7%

Updated

24 Oct, 2021

Data

Company Financials +
AFT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance1/6
Financial Health3/6
Dividends0/6

AFT Overview

AFT Pharmaceuticals Limited develops, licenses, distributes, and sells pharmaceutical products in New Zealand, Australia, Southeast Asia, and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for AFT Pharmaceuticals
Historical stock prices
Current Share PriceNZ$4.10
52 Week HighNZ$4.00
52 Week LowNZ$5.65
Beta0.16
1 Month Change-1.44%
3 Month Change-8.89%
1 Year Change-16.67%
3 Year Change81.42%
5 Year Change33.55%
Change since IPO32.26%

Recent News & Updates

Jul 30
We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

Shareholders will be pleased by the impressive results for AFT Pharmaceuticals Limited ( NZSE:AFT ) recently and CEO...

Jun 02
With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

When close to half the companies in New Zealand have price-to-earnings ratios (or "P/E's") below 21x, you may consider...

Shareholder Returns

AFTNZ PharmaceuticalsNZ Market
7D1.5%0.4%0.4%
1Y-16.7%0.7%2.1%

Return vs Industry: AFT underperformed the NZ Pharmaceuticals industry which returned 0.7% over the past year.

Return vs Market: AFT underperformed the NZ Market which returned 2.1% over the past year.

Price Volatility

Is AFT's price volatile compared to industry and market?
AFT volatility
AFT Beta0.16
Industry Beta1.29
Market Beta1

Stable Share Price: AFT is less volatile than 75% of NZ stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: AFT's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199794Hartley Atkinsonhttps://www.aftpharm.com

AFT Pharmaceuticals Limited develops, licenses, distributes, and sells pharmaceutical products in New Zealand, Australia, Southeast Asia, and internationally. The company offers products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, nail and oral care, pain management, skin care, and other products, as well as supplements. The company was incorporated in 1997 and is headquartered in Auckland, New Zealand.

AFT Pharmaceuticals Fundamentals Summary

How do AFT Pharmaceuticals's earnings and revenue compare to its market cap?
AFT fundamental statistics
Market CapNZ$429.22m
Earnings (TTM)NZ$7.59m
Revenue (TTM)NZ$113.11m

56.5x

P/E Ratio

3.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AFT income statement (TTM)
RevenueNZ$113.11m
Cost of RevenueNZ$64.36m
Gross ProfitNZ$48.74m
ExpensesNZ$41.15m
EarningsNZ$7.59m

Last Reported Earnings

Mar 31, 2021

Next Earnings Date

Nov 17, 2021

Earnings per share (EPS)0.073
Gross Margin43.09%
Net Profit Margin6.71%
Debt/Equity Ratio104.8%

How did AFT perform over the long term?

See historical performance and comparison

Valuation

Is AFT Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

35.7%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AFT (NZ$4.1) is trading below our estimate of fair value (NZ$6.37)

Significantly Below Fair Value: AFT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AFT is poor value based on its PE Ratio (56.5x) compared to the Oceanic Pharmaceuticals industry average (44.9x).

PE vs Market: AFT is poor value based on its PE Ratio (56.5x) compared to the NZ market (22.2x).


Price to Earnings Growth Ratio

PEG Ratio: AFT is poor value based on its PEG Ratio (1.6x)


Price to Book Ratio

PB vs Industry: AFT is overvalued based on its PB Ratio (11.7x) compared to the XO Pharmaceuticals industry average (3.8x).


Future Growth

How is AFT Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

34.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AFT's forecast earnings growth (34.4% per year) is above the savings rate (2.1%).

Earnings vs Market: AFT's earnings (34.4% per year) are forecast to grow faster than the NZ market (9.2% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: AFT's revenue (13.9% per year) is forecast to grow faster than the NZ market (5.3% per year).

High Growth Revenue: AFT's revenue (13.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AFT's Return on Equity is forecast to be high in 3 years time (27.4%)


Past Performance

How has AFT Pharmaceuticals performed over the past 5 years?

57.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AFT has a high level of non-cash earnings.

Growing Profit Margin: AFT's current net profit margins (6.7%) are lower than last year (11.1%).


Past Earnings Growth Analysis

Earnings Trend: AFT has become profitable over the past 5 years, growing earnings by 57.5% per year.

Accelerating Growth: AFT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: AFT had negative earnings growth (-35.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (17.1%).


Return on Equity

High ROE: Whilst AFT's Return on Equity (21.27%) is high, this metric is skewed due to their high level of debt.


Financial Health

How is AFT Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: AFT's short term assets (NZ$67.9M) exceed its short term liabilities (NZ$32.1M).

Long Term Liabilities: AFT's short term assets (NZ$67.9M) exceed its long term liabilities (NZ$36.4M).


Debt to Equity History and Analysis

Debt Level: AFT's debt to equity ratio (104.8%) is considered high.

Reducing Debt: AFT's debt to equity ratio has increased from 82.3% to 104.8% over the past 5 years.

Debt Coverage: AFT's debt is not well covered by operating cash flow (2%).

Interest Coverage: AFT's interest payments on its debt are well covered by EBIT (3.1x coverage).


Balance Sheet


Dividend

What is AFT Pharmaceuticals's current dividend yield, its reliability and sustainability?

1.67%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AFT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AFT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AFT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AFT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AFT's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

9.1yrs

Average management tenure


CEO

Hartley Atkinson

24.08yrs

Tenure

NZ$701,490

Compensation

Dr. Hartley Atkinson, M.Pharm (Dist), PhD, founded AFT Pharmaceuticals Limited in 1997, has been its Chief Executive Officer since September 04, 1997 and also serves as its Managing Director. Before establ...


CEO Compensation Analysis

Compensation vs Market: Hartley's total compensation ($USD500.78K) is about average for companies of similar size in the NZ market ($USD502.43K).

Compensation vs Earnings: Hartley's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: AFT's management team is seasoned and experienced (9.1 years average tenure).


Board Members

Experienced Board: AFT's board of directors are considered experienced (7.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

AFT Pharmaceuticals Limited's employee growth, exchange listings and data sources


Key Information

  • Name: AFT Pharmaceuticals Limited
  • Ticker: AFT
  • Exchange: NZSE
  • Founded: 1997
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NZ$429.224m
  • Shares outstanding: 104.69m
  • Website: https://www.aftpharm.com

Number of Employees


Location

  • AFT Pharmaceuticals Limited
  • 129 Hurstmere Road
  • Level 1
  • Auckland
  • 622
  • New Zealand

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/24 06:00
End of Day Share Price2021/10/22 00:00
Earnings2021/03/31
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.